FDAnews Drug Daily Bulletin

PRECISIONMED, INC. AND DX INNOVATIONS, INC. ANNOUNCE PATENT FILING

June 6, 2006
A A

PrecisionMed, Inc. and Dx INNOVATIONS, Inc. are pleased to announce the results of a collaborative effort that enabled novel diagnostic procedures based on extracellular nucleic acids identified in cerebrospinal fluid. Dx INNOVATIONS' technology detected extracellular free circulating nucleic acids in cerebrospinal fluid that is most likely the product of programmed cell death (apoptosis), a natural process that allows the body to remodel or recycle tissue.
Genetic Engineering News